Biosciences Institute Newcastle University Newcastle upon Tyne United Kingdom

Brno University of Technology Centre of Excellence IT4Innovations Brno Czech Republic

Charles University Hospital Pilsen Czech Republic

Dana Farber Cancer Institute Harvard Medical School Boston MA USA

Department of Biology and Ecology Faculty of Science University of Ostrava Czech Republic

Department of Haematology and Transfusiology University Hospital Bratislava Slovakia

Department of Haematology Medical University of Lodz Copernicus Memorial Hospital Łódź Poland

Department of Haematology Oncology and Internal Diseases Medical University of Warsaw Poland

Department of Haematooncology University Hospital Ostrava Ostrava Czech Republic

Department of Internal Medicine Hematology and Oncology University Hospital Brno Czech Republic

Dept and Clinic of Haematology Blood Neoplasms Wroclaw Medical University Poland

Dept of Haematology and Stem Cell Transplantation South Pest Central Hospital Budapest Hungary

Dept of Hematology and Cancer Prevention Medical University of Silesia in Katowice Poland

Dpt of Clinical studies Faculty of Medicine University of Ostrava Ostrava Czech Republic

Dpt of Medicine Multiple Myeloma Research Perlmutter Cancer Center NYU School of Medicine USA

Institute of Biostatistics and Analyses Masaryk University Brno Czech Republic

Institute of Molecular and Translational Medicine Palacky University Olomouc Czech Republic

IT4Innovations VSB Technical University of Ostrava Ostrava Czech Republic

Jagiellonian University Medical College Cracow Poland

RECETOX Faculty of Science Masaryk university in Brno Brno Czech Republic

Silesian Hospital Opava Opava Czech Republic

Zobrazit více v PubMed

Merlini G, Palladini G. Light chain amyloidosis: the heart of the problem. Haematologica. 2013;98(10):1492-1495. PubMed PMC

Desikan KR, Dhodapkar MV, Hough A, et al. Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation. Leuk Lymphoma. 1997;27(3–4):315-319. PubMed

Jelinek T, Kryukova E, Kufova Z, Kryukov F, Hajek R. Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity. Hematol Oncol. 2017;35(4):408-419. PubMed

Jelinek T, Kufova Z, Hajek R. Immunomodulatory drugs in AL amyloidosis. Crit Rev Oncol Hematol. 2016;99:249-260. PubMed

Babayan A, Alawi M, Gormley M, et al. Comparative study of whole genome amplification and next generation sequencing performance of single cancer cells. Oncotarget. 2016;8(34):56066-56080. PubMed PMC

Itan Y, Shang L, Boisson B, Patin E, et al. The human gene damage index as a gene-level approach to prioritizing exome variants. Proc Natl Acad Sci U S A. 2015;112(44):13615-13620. PubMed PMC

Bolli N, Biancon G, Moarii M, et al. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. 2018;32(12):2604-2616. PubMed PMC

Boyle EM, Ashby C, Wardell CP, et al. The genomic landscape of plasma cells in systemic light chain amyloidosis. Blood. 2018; 132(26):2775-2777. PubMed

Paiva B, Martinez-Lopez J, Corchete LA, et al. Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis. Blood. 2016;127(24):3035-3039. PubMed

Walker BA, Boyle EM, Wardell CP, et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol. 2015; 33(33):3911-3920. PubMed PMC

Kryukov F, Kryukova E, Brozova L, et al. Does AL amyloidosis have a unique genomic profile? Gene expression profiling meta-analysis and literature overview. Gene. 2016;591(2):490-498. PubMed

Crawford DR, Wang Y, Schools GP, Kochheiser J, Davies KJ. Downregulation of mammalian mitochondrial RNAs during oxidative stress. Free Radic Biol Med. 1997;1;22(3):551-559. PubMed

Oliva L, Orfanelli U, Resnati M, et al. The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity. Blood. 2017;129(15):2132-2142. PubMed

Bochtler T, Merz M, Hielscher T, et al. Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma. Blood Adv. 2018;2(20):2607-2618. PubMed PMC